ABSTRACT
BACKGROUND: A keloid is a benign tumor that contains excess collagen, primarily type I collagen. A common therapy is intralesional injection of a glucocorticosteroid, such as triamcinolone acetonide (TA). Surgical excision is also common; often a glucocorticosteroid is injected weeks after excision when wound repair has already begun. OBJECTIVE: Our purpose was to determine the efficacy of TA in reducing the pro-alpha1(I) type I collagen mRNA in the dermis, when TA is injected into the wound bed immediately after surgical excision of the keloid. METHODS: Six patients with previously untreated keloids were studied. Three were treated with 10 mg/ml of TA immediately after excision of the keloid (experimental group); the other three patients were not treated with TA until 2 weeks after excision (control). Punch biopsy specimens were obtained from the TA-treated sites 2 weeks after removal of the keloid and from the wounds of the control group of patients before they were treated with TA. Sections were prepared for in situ hybridization analysis of the pro-alpha1(I) collagen mRNA, as well as for histochemical analysis of collagen fibers. RESULTS: All keloids showed greatly elevated levels of pro-alpha1(I) type I collagen mRNA in the dermis. Postsurgical wounds injected with TA after removal of the keloid expressed decreased pro-alpha1(I) collagen transcripts, compared with skin not treated with TA. The collagen bundles were also thinner and less dense in the TA-treated skin. CONCLUSION: Downregulation of the type I collagen gene expression is elicited by immediate TA injection after keloid excision. This suggests that prevention of recurrent keloid growth is possible if surgical excision is accompanied by immediate TA injection into the wound bed and that healing of the wound is not apparently compromised by inhibition of type I collagen gene expression.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Collagen/drug effects , Glucocorticoids/therapeutic use , Keloid/surgery , Procollagen/drug effects , Skin/drug effects , Triamcinolone Acetonide/therapeutic use , Administration, Topical , Adolescent , Adult , Anti-Inflammatory Agents/administration & dosage , Biopsy , Collagen/analysis , Collagen/genetics , Collagen/ultrastructure , Coloring Agents , Combined Modality Therapy , Down-Regulation , Ear Diseases/drug therapy , Ear Diseases/surgery , Ear, External/surgery , Gene Expression Regulation/drug effects , Glucocorticoids/administration & dosage , Humans , Immunohistochemistry , In Situ Hybridization , Injections, Intralesional , Procollagen/analysis , Procollagen/genetics , Procollagen/ultrastructure , RNA, Messenger/drug effects , RNA, Messenger/genetics , Thorax/pathology , Transcription, Genetic/drug effects , Triamcinolone Acetonide/administration & dosage , Wound Healing/drug effectsSubject(s)
Skin Neoplasms/radiotherapy , Skin/radiation effects , Wound Healing/radiation effects , Wounds and Injuries/radiotherapy , Animals , Humans , Models, Biological , Neoplasms, Radiation-Induced/etiology , Radiation Injuries/therapy , Radiation, Ionizing , Skin/injuries , Skin/pathology , Skin/physiopathology , Time FactorsABSTRACT
Based on cell kinetic, morphological and several biological considerations, we have recently proposed that hair follicle stem cells reside in the bulge area of the upper follicle. We predicted that during early anagen the normally slow-cycling bulge stem cells may be activated by the abutting dermal papilla cells to undergo transient proliferation giving rise to keratinocytes of the lower follicle. In the present work, we performed tritiated thymidine-labeling of DNA-synthesizing cells and colcemid-arrest of mitotic figures on the skins of 20-23 and 75-80 day old SENCAR mice, when the follicles entered the anagen phase of the 2nd and 3rd hair cycles. The results clearly indicate that the normally slow-cycling bulge cells indeed undergo transient proliferation during early anagen. Similar results were obtained when the telogen follicles are experimentally induced to enter the 3rd hair cycle by plucking and by topical applications of phorbol ester or tretinoin. These results support the notion that bulge cells are follicular stem cells, and that transient proliferation of these cells is a critical feature of early anagen. However, the long duration of the 2nd telogen (> 30 days in mouse) suggests that a new anagen phase does not automatically result from the physical proximity of dermal papilla to the bulge cells, and that another 'factor' is required for the initiation of the 3rd anagen. The tremendous difference in the durations of the first and second telogen (lasting for 2-3 days and > 50 days, respectively) suggests that follicles can exist in a non-cycling state that may be conceptually equivalent to the G0 state of the cell cycle. Our results also underscore the fact that the first hair cycle is distinct from all the subsequent hair cycles in their cellular origin and morphological sequence, and thus should be regarded as a neogenic event.